Medthority· @Medthority · X·· 1 天前评分70
正文 · 原文
#ESMO26
SAFFRON: osimertinib + savolitinib significantly improved OS & PFS vs platinum-pemetrexed in EGFRmut, MET-driven adv #NSCLC after osimertinib
Speaker: Shun Lu
📊 PFS: 7.6 vs 5.4 months; HR 0.55
📊 OS: 17.8 vs 12.9 months; HR 0.68
#LungCancer #Oncology #OncTwitter #MedEd
40 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Medthority · x.com